DeCure's autonomous Nephrology AI scientist is researching a drug-repurposing hypothesis for branchio-oto-renal syndrome — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBranchio-oto-renal syndrome maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for branchio-oto-renal syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
transcription factor AP-2 alpha (TFAP2A) — TFAP2A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet pgedrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8J0K · 2.1 Å · ligand TRIETHYLENE GLYCOL (PGE). Experimental structure, not a prediction.
What the evidence adds up to
No drug treatment is mentioned in any of the provided abstracts. The 2014 abstract on belatacept concerns renal transplantation in a different context and does not address branchio-oto-renal syndrome. The 2024 abstract describes characteristic CT findings in branchio-oto-renal or branchio-oto syndrome, including cochlear dysplasia, ossicular chain malformation, and a distended eustachian tube. The 2025 case report describes a 20-year-old Han Chinese female with bilateral preauricular and lateral neck fistulas, cup-shaped right ear deformity, bilateral sensorineural hearing loss, an enlarged vestibular aqueduct, and a hypoplastic left kidney. She underwent bilateral preauricular fistulotomy and bilateral branchial fistulotomy; half a year after surgery the incisions healed well with no discharge or signs of recurrence. The patient did not undergo genetic testing.
The abstracts contain no data on drug repurposing, no response rates, no survival figures, and no controlled trials. There is no evidence that any pharmacological agent alters the course of branchio-oto-renal syndrome. The only interventions described are surgical removal of fistulas. The 2025 report explicitly notes that diagnosis remains challenging due to clinical heterogeneity and that multidisciplinary management — surgery, audiological support, and long-term kidney monitoring — is the current standard.
What is missing is any preclinical or clinical investigation of drug therapy for branchio-oto-renal syndrome. No funding for drug screening, no animal models treated with repurposed compounds, no patient stratification by genotype, and no trial design have been reported in these abstracts. Without such work, no drug can be proposed for this condition.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Journal of Urology · 2014 · 1 citations
Re: Renal Transplantation Using Belatacept without Maintenance Steroids or Calcineurin Inhibitors
[Clinical features and temporal CT findings in patients with Branchio-Oto-Renal or Branchio-Oto Syndrome].
AbstractCochlear dysplasia, ossicular chain malformation and distended eustachian tube comprise the characteristic CT signs of BOS/BORS, which possesses versatile and complex CT findings. Temporal CT can accurately assess the important structures such as cochlea, ossicles, vestibule, semicircular canal, vestibular aqueduct and internal auditory canal. Combing with the clinical characteristics of bilateral, mixed hearing loss, preauricular fistula and branchial fistula can provide valuable information for early diagnosis and treatment.
Journal of Medical Case Reports · 2025 · 0 citations · open access
Branchio-oto-renal syndrome in a young Han Chinese female: a case report and review of the literature
AbstractBACKGROUND: Branchio-oto-renal syndrome is a rare autosomal dominant disorder characterized by branchial arch anomalies, hearing loss, and renal dysplasia. Its diagnosis remains challenging due to clinical heterogeneity and overlapping features with other syndromes. This case report aims to enhance awareness of branchio-oto-renal syndrome and highlight multidisciplinary management strategies. CASE PRESENTATION: A 20-year-old Han Chinese female presented with bilateral preauricular and lateral neck fistulas since birth, accompanied by intermittent discharge. Physical examination revealed cup-shaped right ear deformity, bilateral preauricular fistulas, and branchial fistulas. Audiometry showed bilateral sensorineural hearing loss. Imaging studies identified an enlarged vestibular aqueduct and a hypoplastic left kidney. The patient underwent bilateral preauricular fistulotomy and bilateral branchial fistulotomy. Half a year after surgery, the patient's incision healed well with no discharge or signs of recurrence. Unfortunately, the patient did not undergo genetic testing. CONCLUSION: The diagnosis of branchio-oto-renal syndrome requires a high degree of clinical suspicion. Multidisciplinary collaboration is crucial for comprehensive management, including surgical intervention, audiological support, and long-term kidney monitoring.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
